Pracharova, Jitka, Zerzankova, Lenka, Stepankova, Jana, Novakova, Olga, Farrer, Nicola J., Sadler, P. J., Brabec, Viktor and Kasparkova, Jana. (2012) Interactions of DNA with a new Platinum(IV) Azide Dipyridine complex activated by UVA and visible light : relationship to toxicity in tumor cells. Chemical Research in Toxicology, Vol.25 (No.5). pp. 1099-1111. ISSN 0893-228X

Preview

Text WRAP_Sadler_485_verze z redakce.pdf - Accepted Version Download (1797Kb) | Preview

Abstract

The Pt IV diazido complex trans,trans,trans-[Pt(N 3) 2(OH) 2(pyridine) 2] (1) is unreactive in the dark but is cytotoxic when photoactivated by UVA and visible light. We have shown that 1 when photoactivated accumulates in tumor cells and binds strongly to nuclear DNA under conditions in which it is toxic to tumor cells. The nature of the DNA adducts, including conformational alterations, induced by photoactivated 1 are distinctly different from those produced in DNA by conventional cisplatin or transplatin. In addition, the observation that major DNA adducts of photoactivated 1 are able to efficiently stall RNA polymerase II more efficiently than cisplatin suggests that transcription inhibition may contribute to the cytotoxicity levels observed for photoactivated 1. Hence, DNA adducts of 1 could trigger a number of downstream cellular effects different from those triggered in cancer cells by DNA adducts of cisplatin. This might lead to the therapeutic effects that could radically improve chemotherapy by platinum complexes. The findings of the present work help to explain the different cytotoxic effects of photoactivated 1 and conventional cisplatin and thereby provide new insights into mechanisms associated with the antitumor effects of platinum complexes photoactivated by UVA and visible light. © 2012 American Chemical Society.

Item Type:	Journal Article
Subjects:	Q Science > QD Chemistry Q Science > QP Physiology
Divisions:	Faculty of Science > Chemistry
Library of Congress Subject Headings (LCSH):	Antineoplastic agents, Platinum -- Therapeutic use, Cell-mediated cytotoxicity, DNA damage, RNA polymerases, Photochemistry
Journal or Publication Title:	Chemical Research in Toxicology
Publisher:	American Chemical Society
ISSN:	0893-228X
Date:	2012
Volume:	Vol.25
Number:	No.5
Page Range:	pp. 1099-1111
Identification Number:	10.1021/tx300057y
Status:	Peer Reviewed
Publication Status:	Published
Access rights to Published version:	Restricted or Subscription Access
Funder:	Grantová agentura České republiky [Grant Agency of the Czech Republic] (GACR), European Research Council (ERC), Engineering and Physical Sciences Research Council (EPSRC), Univerzita Palackého v Olomouci
Grant number:	P301/10/0598 (GACR), 301/09/H004 (GACR), 247450 (ERC), EP/G006792/1 (EPSRC)
References:	(1) Bednarski, P. J., Mackay, F. S., and Sadler, P. (2007) Photoactivatable platinum complexes. Anti-Cancer Agents Med. Chem. 7, 75-93. (2) Mackay, F. S., Woods, J. A., Heringova, P., Kasparkova, J., Pizarro, A. M., Moggach, S. A., Parsons, S., Brabec, V., and Sadler, P. J. (2007) A potent cytotoxic photoactivated platinum complex. Proc. Natl. Acad. Sci. USA 104, 20743-20748. (3) Farrer, N. J., Woods, J. A., Salassa, L., Zhao, Y., Robinson, K. S., Clarkson, G. J., Mackay, F. S., and Sadler, P. J. (2010) A potent trans-diimine platinum anticancer complex photoactivated by visible light. Angew. Chem. Int. Ed. 49, 1-5. (4) Kasparkova, J., Novakova, O., Najajreh, Y., Gibson, D., Perez, J.-M., and Brabec, V. (2003) Effects of a piperidine ligand on the mechanism of action of antitumor cisplatin. Chem. Res. Toxicol. 16, 1424-1432. (5) Kasparkova, J., Marini, V., Najajreh, Y., Gibson, D., and Brabec, V. (2003) DNA binding mode of the cis and trans geometries of new antitumor nonclassical platinum complexes containing piperidine, piperazine or 4-picoline ligand in cell-free media. Relations to their activity in cancer cell lines. Biochemistry 42, 6321-6332. (6) Kasparkova, J., Novakova, O., Marini, V., Najajreh, Y., Gibson, D., Perez, J.-M., and Brabec, V. (2003) Activation of trans geometry in bifunctional mononuclear platinum complexes by a piperidine ligand: Mechanistic studies on antitumor action. J. Biol. Chem. 278, 47516-47525. (7) Najajreh, Y., Khazanov, E., Jawbry, S., Ardeli-Tzaraf, Y., Perez, J. M., Kasparkova, J., Brabec, V., Barenholz, Y., and Gibson, D. (2006) Cationic nonsymmetric transplatinum complexes with piperidinopiperidine ligands. Preparation, characterization, in vitro cytotoxicity, in vivo toxicity, and anticancer efficacy studies. J. Med. Chem. 49, 4665-4673. (8) Najajreh, Y., Ardeli-Tzaraf, Y., Kasparkova, J., Heringova, P., Prilutski, D., Balter, L., Jawbry, S., Khazanov, E., Perez, J. M., Barenholz, Y., Brabec, V., and Gibson, D. (2006) Interactions of platinum complexes containing cationic, bicyclic, nonplanar piperidinopiperidine ligands with biological nucleophiles. J. Med. Chem. 49, 4674-4683. (9) Najajreh, Y., Kasparkova, J., Marini, V., Gibson, D., and Brabec, V. (2005) Structural characterization and DNA interactions of new cytotoxic transplatin analogues containing one planar and one nonplanar heterocyclic amine ligand. J. Biol. Inorg. Chem. 10, 722-731. (10) Najajreh, Y., Prilutski, D., Ardeli-Tzaraf, Y., Perez, J.-M., Khazanov, E., Barenholz, Y., Kasparkova, J., Brabec, V., and Gibson, D. (2005) Structure and unique interactions with DNA of a cationic trans-platinum complex with the nonplanar bicyclic piperidinopiperidine ligand. Angew. Chem. Int. Ed. 44, 2-4. (11) Aris, S. M., and Farrell, N. P. (2009) Towards antitumor active trans-platinum compounds. Eur. J. Inorg. Chem. 2009, 1293-1302. (12) Aris, S. M., Knott, K. M., Yang, X., Gewirtz, D. A., and Farrell, N. P. (2009) Modulation of transplanaramine platinum complex reactivity by systematic modification of carrier and leaving groups. Inorg. Chim. Acta 362, 929-934. (13) Zakovska, A., Novakova, O., Balcarova, Z., Bierbach, U., Farrell, N., and Brabec, V. (1998) DNA interactions of antitumor trans-[PtCl2(NH3)(quinoline)]. Eur. J. Biochem. 254, 547-557. (14) Brabec, V., Neplechova, K., Kasparkova, J., and Farrell, N. (2000) Steric control of DNA interstrand cross-link sites of trans platinum complexes: specificity can be dictated by planar nonleaving groups. J. Biol. Inorg. Chem. 5, 364-368. (15) Kasparkova, J., Novakova, O., Farrell, N., and Brabec, V. (2003) DNA binding by antitumor trans-[PtCl2(NH3)(thiazole)]. Protein recognition and nucleotide excision repair of monofunctional adducts. Biochemistry 42, 792-800. (16) Fichtinger-Schepman, A. M. J., Van der Veer, J. L., Den Hartog, J. H. J., Lohman, P. H. M., and Reedijk, J. (1985) Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: Formation, identification, and quantitation. Biochemistry 24, 707-713. (17) Jamieson, E. R., Jacobson, M. P., Barnes, C. M., Chow, C. S., and Lippard, S. J. (1999) Structural and kinetic studies of a cisplatin-modified DNA icosamer binding to HMG1 domain B. J. Biol. Chem. 274, 12346-12354. (18) Comess, K. M., Burstyn, J. N., Essigmann, J. M., and Lippard, S. J. (1992) Replication inhibition and translesion synthesis on templates containing site-specifically placed cisdiamminedichloroplatinum( II) DNA adducts. Biochemistry 31, 3975-3990. (19) Pillaire, M. J., Hoffmann, J. S., Defais, M., and Villani, G. (1995) Replication of DNA containing cisplatin lesions and its mutagenic consequences. Biochimie 77, 803-807. (20) Damsma, G. E., Alt, A., Brueckner, F., Carell, T., and Cramer, P. (2007) Mechanism of transcriptional stalling at cisplatin-damaged DNA. Nature Struct. Mol. Biol. 14, 1127-1133. (21) Todd, R. C., and Lippard, S. J. (2009) Inhibition of transcription by platinum antitumor compounds. Metallomics 1, 280-291. (22) Fuertes, M. A., Castilla, J., Alonso, C., and Perez, J. M. (2003) Cisplatin biochemical mechanism of action: From cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. Curr. Med. Chem. 10, 257-266. (23) Brabec, V., and Palecek, E. (1976) Interaction of nucleic acids with electrically charged surfaces. II. Conformational changes in double-helical polynucleotides. Biophys. Chem. 4, 76-92. (24) Brabec, V., and Palecek, E. (1970) The influence of salts and pH on polarographic currents produced by denatured DNA. Biophysik 6, 290-300. (25) Keck, M. V., and Lippard, S. J. (1992) Unwinding of supercoiled DNA by platinum ethidium and related complexes. J. Am. Chem. Soc. 114, 3386-3390. (26) Brabec, V., and Leng, M. (1993) DNA interstrand cross-links of transdiamminedichloroplatinum( II) are preferentially formed between guanine and complementary cytosine residues. Proc. Natl. Acad. Sci. USA 90, 5345-5349. (27) Lemaire, M. A., Schwartz, A., Rahmouni, A. R., and Leng, M. (1991) Interstrand cross-links are preferentially formed at the d(GC) sites in the reaction between cis-diamminedichloroplatinum(II) and DNA. Proc. Natl. Acad. Sci. USA 88, 1982-1985. (28) Butour, J. L., and Macquet, J. P. (1977) Differentiation of DNA - platinum complexes by fluorescence. The use of an intercalating dye as a probe. Eur. J. Biochem. 78, 455-463. (29) Butour, J. L., Alvinerie, P., Souchard, J. P., Colson, P., Houssier, C., and Johnson, N. P. (1991) Effect of the amine nonleaving group on the structure and stability of DNA complexes with cis-[Pt(RNH2) 2(NO3)2]. Eur. J. Biochem. 202, 975-980. (30) Topal, M. D., and Fresco, J. R. (1980) Fluorescence of terbium ion-nucleic acid complexes: A sensitive specific probe for unpaired residues in nucleic acids. Biochemistry 19, 5531-5537. (31) Balcarova, Z., and Brabec, V. (1989) Reinterpretation of fluorescence of terbium ion - DNA complexes. Biophys. Chem. 33, 55-61. (32) Arquilla, M., Thompson, L. M., Pearlman, L. F., and Simpkins, H. (1983) Effect of platinum antitumor agents on DNA and RNA investigated by terbium fluorescence. Cancer Res. 43, 1211-1216. (33) Kasparkova, J., Mellish, K. J., Qu, Y., Brabec, V., and Farrell, N. (1996) Site-specific d(GpG) intrastrand cross-links formed by dinuclear platinum complexes. Bending and NMR studies. Biochemistry 35, 16705-16713. (34) Brabec, V. (2002) DNA modifications by antitumor platinum and ruthenium compounds: their recognition and repair. Prog. Nucleic Acid Res. Mol. Biol. 71, 1-68. (35) Bancroft, D. P., Lepre, C. A., and Lippard, S. J. (1990) 195Pt NMR kinetic and mechanistic studies of cis-diamminedichloroplatinum and trans-diamminedichloroplatinum(II) binding to DNA. J. Am. Chem. Soc. 112, 6860-6871. (36) Brabec, V., Kleinwächter, V., Butour, J. L., and Johnson, N. P. (1990) Biophysical studies of the modification of DNA by antitumour platinum coordination complexes. Biophys. Chem. 35, 129-141. (37) Eastman, A., and Barry, M. A. (1987) Interaction of trans-diamminedichloroplatinum(II) with DNA: Formation of monofunctional adducts and their reaction with glutathione. Biochemistry 26, 3303- 3307. (38) Prokop, R., Kasparkova, J., Novakova, O., Marini, V., Pizarro, A. M., Navarro-Ranninger, C., and Brabec, V. (2004) DNA interactions of new antitumor platinum complexes with trans geometry activated by a 2-metylbutylamine or sec-butylamine ligand. Biochem. Pharmacol. 67, 1097-1109. (39) Kasparkova, J., Vojtiskova, M., Natile, G., and Brabec, V. (2008) Unique properties of DNA interstrand cross-links of antitumor oxaliplatin and the effect of chirality of the carrier ligand. Chem. Eur. J. 14, 1330-1341. (40) Zerzankova, L., Suchankova, T., Vrana, O., Farrell, N. P., Brabec, V., and Kasparkova, J. (2010) Conformation and recognition of DNA modified by a new antitumor dinuclear PtII complex resistant to decomposition by sulfur nucleophiles. Biochem. Pharmacol. 79, 112-121. (41) Cullinane, C., Mazur, S. J., Essigmann, J. M., Phillips, D. R., and Bohr, V. A. (1999) Inhibition of RNA polymerase II transcription in human cell extracts by cisplatin DNA damage. Biochemistry 38, 6204-6212. (42) Bagchi, M. K., Tsai, S. Y., Weigel, N. L., Tsai, M. J., and O'Malley, B. W. (1990) Regulation of in vitro transcription by progesterone receptor. Characterization and kinetic studies. J. Biol. Chem. 265, 5129-5134. (43) Johnson, N. P., Butour, J.-L., Villani, G., Wimmer, F. L., Defais, M., Pierson, V., and Brabec, V. (1989) Metal antitumor compounds: The mechanism of action of platinum complexes. Prog. Clin. Biochem. Med. 10, 1-24. (44) Jamieson, E. R., and Lippard, S. J. (1999) Structure, recognition, and processing of cisplatin- DNA adducts. Chem. Rev. 99, 2467-2498. (45) Wang, D., and Lippard, S. J. (2005) Cellular processing of platinum anticancer drugs. Nature Rev. Drug Discov. 4, 307-320. (46) Kelland, L. (2007) The resurgence of platinum-based cancer chemotherapy. Nature Rev. Cancer 7, 573-584. (47) Stehliková, K., Kasparkova, J., Novakova, O., Martinez, A., Moreno, V., and Brabec, V. (2006) Recognition of DNA modified by trans-[PtCl2NH3(4-hydroxymethylpyridine)] by tumor suppressor protein p53 and character of DNA adducts of this cytotoxic complex. FEBS J. 273, 301-314. (48) Brabec, V., Kasparkova, J., Vrana, O., Novakova, O., Cox, J. W., Qu, Y., and Farrell, N. (1999) DNA modifications by a novel bifunctional trinuclear platinum Phase I anticancer agent. Biochemistry 38, 6781-6790. (49) Siddik, Z. H. (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22, 7265-7279. (50) Brabec, V., and Kasparkova, J. (2005) Modifications of DNA by platinum complexes: Relation to resistance of tumors to platinum antitumor drugs. Drug Resist. Updates 8, 131-146. (51) Tremeau-Bravard, A., Riedl, T., Egly, J.-M., and Dahmus, M. E. (2003) Fate of RNA polymerase II stalled at a cisplatin lesion. J. Biol. Chem. 279, 7751-7759. (52) Tornaletti, S., Patrick, S. M., Turchi, J. J., and Hanawalt, P. C. (2003) Behavior of T7 RNA polymerase and mammalian RNA polymerase II at site-specific cisplatin adducts in the template DNA. J. Biol. Chem. 278, 35791-35797. (53) Jung, Y., and Lippard, S. J. (2007) Direct cellular responses to platinum-induced DNA damage. Chem. Rev. 107, 1387-1407. (54) Lovejoy, K. S., Todd, R. C., Zhang, S. Z., McCormick, M. S., D'Aquino, J. A., Reardon, J. T., Sancar, A., Giacomini, K. M., and Lippard, S. J. (2008) cis-diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospects. Proc. Natl. Acad. Sci. USA 105, 8902-8907. (55) Lee, K. B., Wang, D., Lippard, S. J., and Sharp, P. A. (2002) Transcription-coupled and DNA damage dependent ubiquitination of RNA polymerase II in vitro. Proc. Natl. Acad. Sci. U.S.A. 99, 4239- 4244. (56) Garner, M. M., and Burg, M. B. (1994) Macromolecular crowding and confinement in cells exposed to hypertonicity. Am. J. Physiol. 266, C877-C892. (57) Zhai, X. Q., Beckmann, H., Jantzen, H. M., and Essigmann, J. M. (1998) Cisplatin-DNA adducts inhibit ribosomal RNA synthesis by hijacking the transcription factor human upstream binding factor. Biochemistry 37, 16307-16315. (58) Ise, T., Nagatani, G., Imamura, T., Kato, K., Takano, H., Nomoto, M., Izumi, H., Ohmori, H., Okamoto, T., Ohga, T., Uchiumi, T., Kuwano, M., and Kohno, K. (1999) Transcription factor Y-box binding protein 1 binds preferentially to cisplatin-modified DNA and interacts with proliferating cell nuclear antigen. Cancer Res. 59, 342-346. (59) Stehlikova, K., Kostrhunova, H., Kasparkova, J., and Brabec, V. (2002) DNA bending and unwinding due to the major 1,2-GG intrastrand cross-link formed by antitumor cisdiamminedichloroplatinum( II) are flanking-base independent. Nucleic Acids Res. 30, 2894-2898. (60) Donahue, B. A., Augot, M., Bellon, S. F., Treiber, D. K., Toney, J. H., Lippard, S. J., and Essigmann, J. M. (1990) Characterization of a DNA damage-recognition protein from mammalian cells that binds specifically to intrastrand d(GpG) and d(ApG) DNA adducts of the anticancer drug cisplatin. Biochemistry 29, 5872-5880. (61) Pil, P. M., and Lippard, S. J. (1992) Specific binding of chromosomal protein-HMG1 to DNA damaged by the anticancer drug cisplatin. Science 256, 234-237. (62) Kasparkova, J., and Brabec, V. (1995) Recognition of DNA interstrand cross-links of cisdiamminedichloroplatinum( II) and its trans isomer by DNA- binding proteins. Biochemistry 34, 12379- 12387. (63) Jung, Y., and Lippard, S. J. (2006) RNA polymerase II blockage by cisplatin-damaged DNA - Stability and polyubiquitylation of stalled polymerase. J. Biol. Chem. 281, 1361-1370. (64) Eastman, A. (1987) The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. Pharm. Ther. 34, 155-166.
URI:	http://wrap.warwick.ac.uk/id/eprint/46584

Request changes to a record

Actions (login required)

View Item